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Receptor binding largely governs HIV tropism since
the presence of CD4 and an appropriate coreceptor,
most often CCR5 or CXCR4, is a prerequisite for efficient
membrane fusion and human immunodeficiency virus
(HIV) infection (Alkhatib et al., 1996; Choe et al., 1996;
Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996;
Feng et al., 1996). Binding of the viral envelope (Env)
protein to CD4 induces conformational changes in the
gp120 subunit of Env that enable it to interact efficiently
with a coreceptor (Lapham et al., 1996; Trkola et al., 1996;
Wu et al., 1996). CD4 binding may also trigger conforma-
tional changes in gp41 that lead to exposure of the fusion
peptide (Furuta et al., 1998; Melikyan et al., 2000). While
the structural consequences of coreceptor binding are
not well understood, it is clear that binding to coreceptor
is needed for the final conformational changes in Env
that lead to membrane fusion and virus entry. Inhibitors
that prevent Env-coreceptor binding or that directly block
conformational changes in Env needed for membrane
fusion have been developed and are now in clinical trials
(Doranz et al., 2001; Kilby et al., 1998).
While engagement of CD4 and a coreceptor is re-
quired for efficient virus entry, simple attachment of HIV
to the cell surface can occur via interactions with other
cell surface molecules (reviewed in Ugolini et al., 1999).
Attachment can be rate limiting for viral infection as
evidenced by the fact that procedures which concentrate
virus on the cell surface in vitro, such as spinoculation or
inclusion of polycations in the virus inoculum, can mark-
edly improve infection efficiency (O’Doherty et al., 2000).
Binding of HIV to cell surface molecules such as heparan
sulfate, or the inclusion of cellular adhesion proteins
such as CD44, ICAM-1, or CD62L in the viral envelope,
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1can also make infection more efficient (reviewed in Hioe
et al., 1998). Cell-derived molecules acquired by HIV can
retain their biological activities when incorporated into
virus particles. For example, CD44 incorporated into the
HIV virion is capable of binding its ligand, hyaluronic acid
(Guo and Hildreth, 1995). Furthermore, anti-CD44 mono-
clonal antibodies (mAbs) can inhibit macrophage and
monocyte infection by R5 virus strains produced in cells
overexpressing CD44 (Rivadeneira et al., 1995). Similarly,
antisera to MHC class I and II molecules were found to
inhibit infection by HIV in vitro and MHC class II proteins
on the HIV virion can enhance virus infection (Arthur et
al., 1992; Cantin et al., 1997a,b). The involvement of virion
associated ICAM-1 in the entry process of HIV has also
been demonstrated, with ICAM-11 virions exhibiting en-
hanced infectivity relative to ICAM-12 virus particles (For-
in et al., 1997; Rizzuto and Sodroski, 1997). Conversely,
FA-1, a ligand for ICAM-1, can promote HIV infection
hen expressed on target cells (Hioe et al., 2001). In
ost instances, these studies have employed virus par-
icles produced in cells that over express the protein of
nterest. Whether incorporation of these molecules oc-
urs to a significant extent in vivo is not known.
A particularly striking example of how attachment per
e can have important consequences for HIV infection
omes from studies with dendritic cells (DCs). Binding
IV to DCs strongly enhances infection of cocultured,
eceptor-positive target cells such as PBMCs even
hough the DCs themselves are either not infected or
nfected inefficiently (Ayehunie et al., 1997; Cameron et
l., 1992; Canque et al., 1999; Geijtenbeek et al., 2000a;
ranelli-Piperna et al., 1998; Weissman et al., 1995).
sing this type of experimental system, productive infec-
ion of PBMCs occurs with amounts of virus that are not
ufficient to initiate infection when applied directly to
ctivated T-cells. Thus, transmission of HIV-1 from DCs
o target cells is very efficient. A protein expressed on the
urface of DCs, termed DC-SIGN for dIendritic cIell-spe-
ific ICAM-3 grabbing nIonintegrin, is largely responsiblefor the ability of DCs to efficiently transmit virus to other
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2 MINIREVIEWcell types (Geijtenbeek et al., 2000a). A closely related
homologue, termed DC-SIGNR, also binds and transmits
primate lentiviruses (Po¨hlmann et al., 2001b). The poten-
tial impact of these virus attachment factors for sexual
and vertical transmission of HIV as well as potential
implications for viral tropism, virus neutralization, and the
application of entry inhibitors are the subjects of this
review.
DC-SIGN IS AN EFFICIENT ATTACHMENT FACTOR
DC-SIGN is a 404-amino-acid-long type II integral
membrane protein that binds to ICAM-3 (Fig. 1). As a
result, it may help mediate initial interactions between
DCs and other cell types (Geijtenbeek et al., 2000b). Its
ctodomain contains seven complete and one incom-
lete copy of a 23-residue motif and a C-type (i.e., cal-
ium dependent) lectin domain. DC-SIGN mediates bind-
ng of primary R5, X4, and R5X4 HIV-1 strains as well as
IV-2 and SIV strains to the cell surface, indicating that
his molecule may function as a universal attachment
actor for primate lentiviruses (Geijtenbeek et al., 2000a;
FIG. 1. Facts and questions for the HIV attachment factors DC-SIGN
IGNR with HIV leading to the transmission in trans to a CD41 corecep
omain; RD, repeat domain; LD, lectin domain.o¨hlmann et al., 2001a). Virus binding is dependent upon
he presence of the lectin domain (Po¨hlmann et al.,
b
u001a) and can be abrogated by preincubation with
GTA and mannan, indicating that recognition of carbo-
ydrates in the viral envelope by the lectin domain is
ikely involved (Geijtenbeek et al., 2000a; Po¨hlmann et al.,
001a). Thus far, DC-SIGN has been shown to bind to
p120 (Geijtenbeek et al., 2000a). Whether it also binds
o gp41 or to glycoproteins of other viruses is not known.
n addition, it is not clear if DC-SIGN–Env interactions are
olely the result of carbohydrate recognition, or if other
tructural features in Env make it a specific ligand for
C-SIGN.
DC-SIGN is expressed both on mature and immature
Cs, although expression levels diminish when DCs
ature (Geijtenbeek et al., 2000a). A subpopulation of
D341 bone-marrow-derived DCs also expresses DC-
IGN (Geijtenbeek et al., 2000a). In situ staining has
ocumented DC-SIGN expression in DC subsets present
n the T-cell area of tonsils, lymph nodes and spleen
Geijtenbeek et al., 2000a). In skin, DC-SIGN expression
s found in dermal DCs whereas Langerhans cells in the
pidermis do not express it at detectable levels (Geijten-
-SIGNR. Schematic representation of the interaction of DC-SIGN/DC-
cell. The important questions raised in this review are listed. ND, neckand DC
1eek et al., 2000a). In mucosal tissues such as rectum,
terus, and cervix, DC-SIGN is abundantly expressed by
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3MINIREVIEWDCs present in the lamina propria (Geijtenbeek et al.,
2000a). In addition, DC-SIGN expression was detected
on some types of macrophages in vivo, including decid-
ual macrophages and Hofbauer cells in the placenta
(Soilleux et al., 2001). It will be important to determine if
DC-SIGN is expressed on other cell types in vivo, if its
expression can be induced under certain conditions, and
how its expression on DCs and macrophages is regu-
lated. DC-SIGN also seems to protect bound virus from
inactivation since virus-pulsed DCs can efficiently trans-
mit virus even when receptor positive cells are added up
to 5 days later (Geijtenbeek et al., 2000a). Thus, virus
bound to DCs via DC-SIGN remains in a transmittable
form for a considerable length of time. Importantly, bind-
ing of HIV or SIV to DC-SIGN does not obviate the need
for CD4 and coreceptor binding in that transmission
occurs only to cells that bear the correct virus receptors
(Geijtenbeek et al., 2000a). However, antibodies to DC-
SIGN can significantly reduce binding of virus to DCs
and, as a result, virus transmission. Therefore, DC-SIGN
appears to be largely responsible for the ability of DCs to
efficiently mediate infection of T-cells in trans (Geijten-
beek et al., 2000a).
DC-SIGN AND SEXUAL TRANSMISSION OF HIV
The presence of DC-SIGN on mucosal dendritic cells
and its ability to efficiently bind and transmit virus could
be important for sexual transmission of HIV. DCs are
highly mobile cells, which migrate from peripheral mu-
cosal tissues to the lymph node upon the encounter of
antigen (reviewed in Steinman and Inaba, 1999). Since
dendritic cells are among the first cells encountered by
HIV-1 during sexual transmission, it has been speculated
that virus bound by DC-SIGN may ultimately be ferried to
lymph nodes and gut associated lymphoid tissue as a
consequence of the normal cellular trafficking of DCs
(Geijtenbeek et al., 2000a). The SIV/macaque system
should make it possible to directly test the role of DC-
SIGN in virus transmission. Soluble forms of DC-SIGN,
mAbs that prevent virus-DC-SIGN interactions, or other
compounds that block DC-SIGN recognition of virus will
be needed for such studies.
The potential role of DC-SIGN in virus transmission or
disease progression might also be approached through
correlative studies. Relatively high levels of DC-SIGN are
needed for efficient virus binding and transmission (Po¨hl-
mann et al., 2001a). Thus, as for CCR5, differences in
expression levels between individuals could have impor-
tant consequences (Reynes et al., 2000; Wu et al., 1997).
It will be important to determine if there is much variabil-
ity in levels of DC-SIGN expression between individuals,
and if so to determine if there is a correlation between
DC-SIGN expression levels and virus transmission, dis-
ease progression, or other clinical outcomes. In addition,
if there are differences in how viruses interact with DC-SIGN, this could influence which virus types are trans-
mitted. Thus, viruses (both HIV and SIV) isolated early
after transmission could be tested to determine if they
interact with DC-SIGN or its homologue DC-SIGNR more
efficiently than other virus types. To do this, it will be
important to study these interactions under conditions
where DC-SIGN expression levels are not saturating.
DC-SIGNR, A HOMOLOGUE OF DC-SIGN, ALSO
BINDS AND TRANSMITS HIV AND SIV
A homologue of DC-SIGN, termed DC-SIGNR (for DC-
SIGNRI elated), that exhibits 77% amino acid identity with
DC-SIGN has been recently described (Soilleux et al.,
2000). The genes for DC-SIGN and DC-SIGNR are highly
similar and map within a 30-kb region on chromosome
19p13.2-3, suggesting that duplication of an ancestral
gene may have occurred (Soilleux et al., 2000). Like
C-SIGN, DC-SIGNR also binds to ICAM-3 and functions
s a universal attachment factor for primate lentiviruses,
eing able to bind and transmit multiple HIV-1, HIV-2, and
IV strains to receptor positive cell lines and to human
BMCs (Lin et al., 2000; Po¨hlmann et al., 2001b). How-
ever, the extent of virus transmission to PBMCs from
DC-SIGNR expressing cells appears to be more variable
compared to virus transmission by DC-SIGN positive
cells (Po¨hlmann et al., 2001b). Therefore, DC-SIGNR may
be more selective than DC-SIGN with regard to the virus
strains it can efficiently bind and transmit. To accurately
discern this, however, it will be necessary to study virus
binding and transmission using multiple cell types and to
correlate expression levels with function.
DC-SIGNR is expressed on sinusoidal endothelial
cells in the liver, endothelial cells present in lymph node
sinuses, and a significant proportion of capillary endo-
thelial cells in term placenta (Po¨hlmann et al., 2001b).
Expression of DC-SIGNR on DCs or in other tissues has
not yet been demonstrated, though the development of
additional antisera or monoclonal antibodies may reveal
expression in other locations or under specific condi-
tions. Thus, its expression pattern is quite distinct from
that of DC-SIGN (Po¨hlmann et al., 2001b; Soilleux et al.,
2000). Since lymph nodes represent the major site of HIV
replication in vivo (Fauci, 1996), the presence of DC-
SIGNR on the surface of endothelial cells in lymph node
sinuses represents an obvious mechanism by which
virus can be transmitted to CD4-positive cells that traffic
into lymph nodes via the afferent lymphatics. In addition,
since DC-SIGNR binds to ICAM-3 and may bind to other
cell surface receptors, interactions between T-cells and
the endothelial cell surface may occur more frequently,
increasing the likelihood of virus transmission. The rel-
evance of DC-SIGNR expression on hepatic sinusoidal
endothelial cells for HIV pathogenesis is less obvious,
though there is at least one report that these cells may
be infected by HIV-1 in vitro (Steffan et al., 1992). In
4 MINIREVIEWaddition, hepatic endothelial cells may also be involved
in antigen presentation, perhaps presenting opportuni-
ties to transmit virus to circulating CD4-positive cells
(Knolle and Gerken, 2000; Knolle et al., 1999).
DC-SIGN, DC-SIGNR, AND VERTICAL
TRANSMISSION OF HIV
Vertical transmission of HIV can occur by transplacen-
tal spread of HIV, though the precise mechanism is not
known (Moussa et al., 1999; Thorne and Newell, 2000;
Newell, 1998). Treatment with HAART (highly active an-
tiretroviral therapy) reduces the vertical transmission
rate from 15–20 to 1.5–2% (Dorenbaum, 2001). It is as-
sumed that this residual low level of transmission is a
consequence of in utero (presumed transplacental) in-
fection (Dorenbaum, 2001). The presence of both DC-
SIGN and DC-SIGNR in the placenta could impact verti-
cal transmission of HIV by concentrating virus on the
maternal side of the circulation and perhaps by increas-
ing local transmission of virus to circulating T-cells. In
addition, the presence of DC-SIGN on decidual macro-
phages and Hofbauer cells, which express CD4 and
coreceptors, could make these cells more susceptible to
infection by virus that has traversed the trophoblast layer.
Alternatively, virus bound to these cells via DC-SIGN
could be transmitted to other CD4-positive cell types.
Whether viruses that are vertically transmitted interact
with DC-SIGN or DC-SIGNR more efficiently than viruses
which are not transmitted is not known, but is clearly an
important point to consider.
ATTACHMENT RECONSIDERED
The impressive abilities of DC-SIGN and DC-SIGNR to
increase infection efficiency underscore the importance
of virus attachment as a first step in the infectious entry
pathway. The discovery of these proteins stresses the
need to reexamine virus attachment in general, not only
to receptor-positive cells, but also to cells that frequently
come into contact with them. Indeed, CD4-positive and
coreceptor-negative cells can transfer bound virus to
CD4-negative, coreceptor-positive cells, an example
where a virus receptor on one cell can function in trans
to support infection of an adjoining cell (Speck et al.,
1999). DC-SIGN and DC-SIGNR also support infection in
trans, but do not obviate the need for either CD4 or
coreceptor for viral entry (Geijtenbeek et al., 2000a; Po¨hl-
mann et al., 2001a,b). The precise mechanisms by which
DC-SIGN and DC-SIGNR bind virus are not known be-
yond the obvious dependence on carbohydrate recogni-
tion. It is also not clear why binding of HIV to these virus
attachment factors improves infection efficiency. Per-
haps interactions between these attachment factors with
receptors on target cells such as ICAM-3 bring the cells
into sufficiently close proximity over a wide enough area
that virus may encounter CD4 and coreceptors moreefficiently. If so, the efficiency with which DC-SIGN and
DCSIGNR transmit virus may exhibit considerable vari-
ability depending on the nature of the target cell and its
activation state. Alternatively, DC-SIGN binding could
alter Env conformation in a manner that enables Env to
bind to its receptors more readily or that makes Env more
fusogenic. Identifying the sites on gp120 to which DC-
SIGN binds and the structural consequences of this
interaction will be needed to fully understand how these
proteins function as virus transmission factors.
POTENTIAL IMPACT ON VIRUS NEUTRALIZATION
AND TROPISM
Attachment of virus to the cell surface, be it via DC-
SIGN, DC-SIGNR, or other molecules, has the potential
to influence the efficiency with which virus is neutralized
by either antibodies or entry inhibitors. In several in-
stances, the presence of adhesion molecules on target
cells or in virus particles has been shown to hinder
neutralization (Gomez and Hildreth, 1995; Hioe et al.,
1998, 1999; Rizzuto and Sodroski, 1997). Binding of virus
to DC-SIGN could alter the conformation of Env, affecting
antibody reactivity. DC-SIGN could also prevent subse-
quent binding of neutralizing antibodies simply by steric
hindrance or reduced accessibility due to the close as-
sociation between the virus and the cell surface. In the
case of DCs, HIV may be internalized upon binding
DC-SIGN, only to be returned to the cell surface when
the DC traffics to lymph nodes and interacts with T-cells.
This might also make virus more neutralization resistant.
Conversely, might it be possible to identify specific anti-
bodies that prevent HIV from interacting with DC-SIGN?
Such antibodies may not be neutralizing, but if they
prevent virus binding to these cell surface attachment
factors, they could limit HIV transmission from dendritic
cells to receptor positive T-cells, resulting in decreased
virus infection and perhaps virus load.
Efficient attachment of virus to the cell surface may
also affect susceptibility to entry inhibitors. If DC-SIGN
increases the rate of Env-induced membrane fusion,
structural intermediates of the fusion process which are
targets for antiviral agents such as the fusion inhibitor
T20 will be shorter lived. In addition, we have found that
coexpression of CD4 and DC-SIGN can in some cases
markedly improve the efficiency with which viruses can
infect cells via alternative coreceptors such as STRL33.
This could affect viral tropism as well as sensitivity to
coreceptor antagonists. With a single exception (Sharron
et al., 2000), HIV invariably infects human PBMCs and
monocyte derived macrophages via either CCR5 or
CXCR4. However, some SIV strains can infect human
PBMCs by utilizing an alternative coreceptor such as
STRL33 (Chen et al., 1997; Kirchhoff et al., 1997; Sharron
et al., 2000), indicating that some receptors are ex-
pressed on CD4-positive cell types at levels sufficiently
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5MINIREVIEWhigh to support virus entry. The presence of DC-SIGN on
the surface of some tissue macrophages may enable
virus to infect these cells through the use of coreceptors
other than CCR5 or CXCR4.
The abilities of DC-SIGN and DC-SIGNR to enable
different cell types to capture primate lentiviruses and to
transmit them to receptor positive cells raise obvious
questions about their roles in virus transmission and
pathogenesis in vivo, as well as the possibility that other
pathogens may utilize these or related proteins as at-
tachment or transmission factors. If so, DC-SIGN and
DC-SIGNR could represent new therapeutic targets for
antiviral therapy. More efficient attachment of HIV to the
cell surface via interactions with DC-SIGN and DC-
SIGNR could also impact tropism by enabling virus to
utilize additional coreceptors, as well as reduce the
effectiveness of entry inhibitors and neutralizing antibod-
ies. In addition, if their binding mechanisms are more
clearly defined, DC-SIGN could be used to more effi-
ciently target vaccine components to DCs, which are
potent antigen presenting cells capable of initiating pri-
mary immune responses (reviewed in Banchereau et al.,
2000). Processing and presentation of the vaccine to
helper T cells by DCs could elicit a potent immune
response via effective DC-T–B cell interactions (Fayette
et al., 1997). Therefore, the functional characterization of
C-SIGN and DC-SIGNR has relatively broad implica-
ions for understanding HIV/SIV tropism, pathogenesis,
nd transmission as well as for DC biology and vaccine
evelopment.
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